search
Back to results

Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial (PANDA)

Primary Purpose

Preeclampsia Severe, Preeclampsia Postpartum

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ibuprofen 600 mg
Ketorolac
Acetaminophen
Oxycodone
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Preeclampsia Severe focused on measuring NSAIDs, Ibuprofen

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women at > 23 weeks gestational age undergoing vaginal or cesarean delivery at Barnes-Jewish Hospital with:
  • An antepartum diagnosis of preeclampsia with severe features
  • Pre-eclampsia with severe features will be defined as:
  • Elevated blood pressure ≥ 160/110, or
  • Pre-eclampsia in the setting of thrombocytopenia (platelet count < 100,000), or
  • Impaired liver function (AST elevated to twice upper limit of normal), or
  • Persistent epigastric pain, or
  • Renal insufficiency (serum creatinine of 1.1 mg/dl or doubling of prior value), or
  • Pulmonary edema, or
  • New onset visual disturbance or headache unresponsive to therapy.

Exclusion Criteria:

  • NSAID allergy
  • Allergy to acetaminophen
  • Antihypertensive use in this pregnancy prior to 20 weeks gestation
  • Chronic kidney disease or Acute kidney injury with Creatine clearance less than 60 mL/min
  • Inability to obtain consent
  • Opioid abuse disorder
  • Peptic ulcer disease.

Sites / Locations

  • Barnes Jewish HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

NSAID Analgesic bundle

NSAID free analgesic bundle

Arm Description

Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery

Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.

Outcomes

Primary Outcome Measures

postpartum antihypertensive requirements
measurement of anti-hypertensive requirements at time of discharge

Secondary Outcome Measures

Postpartum pain scores
Evaluate the effect of NSAIDs on patient perception of pain
Postpartum opioid use
Compare the opioid requirements in each arm
Mean arterial blood pressure
Compare peak, average and median MAPs postpartum
End organ damage
Evaluate for evidence of renal, hepatic or neurological injury in the poatpartum period
Hospital readmission
Evaluate the incidence of hospital readmission rate postpartum
Continued anti-hypertensive requirement
evaluate the need for antihypertensive medications at 6 weeks postpartum

Full Information

First Posted
May 18, 2019
Last Updated
February 16, 2023
Sponsor
Washington University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT03978767
Brief Title
Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial
Acronym
PANDA
Official Title
Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 10, 2019 (Actual)
Primary Completion Date
October 27, 2023 (Anticipated)
Study Completion Date
December 27, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomized non-inferiority trial of women with preeclampsia with severe features to determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior to standard analgesic bundles in their impact on postpartum hypertension.
Detailed Description
Recently published clinical guidelines for the care of women with hypertensive disorders recommended that nonsteroidal anti-inflammatory drugs (NSAIDs) should be withheld from patients with hypertension that persists for more than one day postpartum (1). This recommendation is based in data from the general medicine literature, which suggests a role of NSAIDs in precipitating hypertension in non-pregnant adults (2,3). It may also draw from previously published case reports of post-partum hypertension that were thought to be NSAID induced (4). There has been a paucity of data from the obstetric literature to support or rebuff this recommendation. As the opioid crisis worsens in the United States, additional attention and resources have focused on limiting the use of narcotic medications. The effective employment of non-opioid analgesics has been shown to reduce narcotic use (5). Ibuprofen and other NSAIDs are the most effective and most commonly prescribed analgesics for postpartum pain, but clinicians now find themselves stuck between these recommendations and their efforts to limit unnecessary opioid prescriptions. The investigators propose a randomized controlled non-inferiority trial of women with preeclampsia comparing a postpartum analgesic protocol that includes NSAIDs, to one that excludes them. The central hypothesis is that NSAID use does not worsen hypertensive diseases of pregnancy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preeclampsia Severe, Preeclampsia Postpartum
Keywords
NSAIDs, Ibuprofen

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized non-inferiority clinical trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
286 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NSAID Analgesic bundle
Arm Type
Experimental
Arm Description
Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery
Arm Title
NSAID free analgesic bundle
Arm Type
Active Comparator
Arm Description
Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.
Intervention Type
Drug
Intervention Name(s)
Ibuprofen 600 mg
Intervention Description
NSAID pain medication to be used in the experimental bundle for postpartum analgesia
Intervention Type
Drug
Intervention Name(s)
Ketorolac
Intervention Description
NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
Intervention Type
Drug
Intervention Name(s)
Acetaminophen
Intervention Description
Analgesic medication to be used in both treatment arms
Intervention Type
Drug
Intervention Name(s)
Oxycodone
Intervention Description
Analgesic medication to be used in both treatment arms
Primary Outcome Measure Information:
Title
postpartum antihypertensive requirements
Description
measurement of anti-hypertensive requirements at time of discharge
Time Frame
at the end of hospitalization, up to 7 days after randomization
Secondary Outcome Measure Information:
Title
Postpartum pain scores
Description
Evaluate the effect of NSAIDs on patient perception of pain
Time Frame
From randomization to 6 weeks after randomization
Title
Postpartum opioid use
Description
Compare the opioid requirements in each arm
Time Frame
From randomization to 6 weeks after randomization
Title
Mean arterial blood pressure
Description
Compare peak, average and median MAPs postpartum
Time Frame
From randomization to 6 weeks after randomization
Title
End organ damage
Description
Evaluate for evidence of renal, hepatic or neurological injury in the poatpartum period
Time Frame
during hospitalization, an average of 4 days
Title
Hospital readmission
Description
Evaluate the incidence of hospital readmission rate postpartum
Time Frame
From randomization to 6 weeks after randomization
Title
Continued anti-hypertensive requirement
Description
evaluate the need for antihypertensive medications at 6 weeks postpartum
Time Frame
up to 6 weeks

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women at > 23 weeks gestational age undergoing vaginal or cesarean delivery at Barnes-Jewish Hospital with: An antepartum diagnosis of preeclampsia with severe features Pre-eclampsia with severe features will be defined as: Elevated blood pressure ≥ 160/110, or Pre-eclampsia in the setting of thrombocytopenia (platelet count < 100,000), or Impaired liver function (AST elevated to twice upper limit of normal), or Persistent epigastric pain, or Renal insufficiency (serum creatinine of 1.1 mg/dl or doubling of prior value), or Pulmonary edema, or New onset visual disturbance or headache unresponsive to therapy. Exclusion Criteria: NSAID allergy Allergy to acetaminophen Antihypertensive use in this pregnancy prior to 20 weeks gestation Chronic kidney disease or Acute kidney injury with Creatine clearance less than 60 mL/min Inability to obtain consent Opioid abuse disorder Peptic ulcer disease.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jonathan S Hirshberg, MD
Phone
314-362-5000
Email
jhirshberg@wustl.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Tracy Burger
Phone
3147471390
Email
tburger@wustl.edu
Facility Information:
Facility Name
Barnes Jewish Hospital
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan Hirshberg, MD
Phone
314-362-5000
Email
jhirshberg@wustl.edu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24150027
Citation
Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88. No abstract available.
Results Reference
background
PubMed Identifier
23403779
Citation
Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013 Apr;25(2):124-32. doi: 10.1097/GCO.0b013e32835e0ef5.
Results Reference
background
PubMed Identifier
15733721
Citation
Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005 Feb 26-Mar 4;365(9461):785-99. doi: 10.1016/S0140-6736(05)17987-2.
Results Reference
background
PubMed Identifier
29045342
Citation
Mogos MF, Salemi JL, Spooner KK, McFarlin BL, Salihu HH. Hypertensive disorders of pregnancy and postpartum readmission in the United States: national surveillance of the revolving door. J Hypertens. 2018 Mar;36(3):608-618. doi: 10.1097/HJH.0000000000001594.
Results Reference
background
PubMed Identifier
28885417
Citation
Viteri OA, England JA, Alrais MA, Lash KA, Villegas MI, Ashimi Balogun OA, Chauhan SP, Sibai BM. Association of Nonsteroidal Antiinflammatory Drugs and Postpartum Hypertension in Women With Preeclampsia With Severe Features. Obstet Gynecol. 2017 Oct;130(4):830-835. doi: 10.1097/AOG.0000000000002247.
Results Reference
background

Learn more about this trial

Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial

We'll reach out to this number within 24 hrs